Efficacy and Tolerability of Oral Zolmitriptan in Menstrually Associated Migraine: A Randomized, Prospective, Parallel‐Group, Double‐blind, Placebo‐Controlled Study

Loder, Elizabeth; Silberstein, Stephen D.; Abushakra, Susan; Mueller, Loretta; Smith, Timothy R.

doi:10.1111/j.1526-4610.2004.04027.x

Cited by 76 publications

(64 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 2-hours, headaches were still responsive in 48% of zolmitriptan treated attacks as compared with 27% with placebo. 86 Although there are no direct comparator studies between any triptans for short-term prophylaxis of MRM, frovatriptan, sumatriptan, naratriptan and zolmitriptan have shown to be effective short-term prophylactic agents for MRM. [87][88][89][90] Tuchman et al evaluated the effi cacy of zolmitriptan for the shortterm prophylaxis of MRM.…”

Section: Effi Cacy In Menstrually-related Migrainementioning

confidence: 99%

A Review of the Pharmacokinetics, Pharmacodynamics and Efficacy of Zolmitriptan in the Acute Abortive Treatment of Migraine

Kalanuria

Peterlin

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Migraine is a common and often disabling neurovascular disorder. Changes in the metabolism and the central processing of serotonin, as well as abnormalities in the modulation of the central and peripheral trigeminal nociceptive pathways, have been shown to play signifi cant roles in migraine pathophysiology. Recent evidence suggests that a low serotonin state facilitates activation of the trigeminal nociceptive pathways. In addition, several pharmacological agents that modulate serotonin are used in the treatment of migraine. Specifi cally there are seven FDA approved, 5-hydroxytryptamine (5-HT) 1B/1D receptor agonists, used for the acute abortive therapy of migraine. Zolmitriptan is one such triptan. Zolmitriptan is available as a tablet, orally disintegrating tablet and as a nasal spray. It is rapidly absorbed and detectable within the plasma, within 2 to 5 minutes for the nasal spray and within 15 minutes for the tablet. Zolmitriptan reaches peak plasma levels in 2-4 hours, with good levels maintained for up to 6 hours. Although the metabolism of zolmitriptan is predominantly hepatic, only 25% of zolmitriptan is bound to plasma proteins. Thus it is unlikely for drug interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is very well tolerated with less than half of participants in clinical trials reporting adverse events, most of which were mild and transient. Although rare, serious cardiovascular events have been reported with all triptans. However, when patients are appropriately selected, zolmitriptan is both, a safe and effective acute migraine abortive agent. In this article, we will fi rst briefl y review the biological role of serotonin and the literature linking serotonin to migraine pathophysiology. This will be followed by a comprehensive review of the pharmacodynamics, pharmacokinetics and effi cacy of zolmitriptan. Finally, the clinical application of the use of zolmitriptan in migraine therapy will be discussed.

show abstract

Section: Effi Cacy In Menstrually-related Migrainementioning

confidence: 99%

A Review of the Pharmacokinetics, Pharmacodynamics and Efficacy of Zolmitriptan in the Acute Abortive Treatment of Migraine

Kalanuria

Peterlin

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

show abstract

“…Several triptans have been assessed for efficacy in the short-term prevention of migraine associated with menses [Newman et al, 2001;Silberstein et al, 2004b, Loder et al, 2004. Naratriptan and frovatriptan have been reported to be effective in short-term prophylaxis of menstrually associated migraine.…”

Section: Triptansmentioning

confidence: 99%

Newer aspects of migraine preventive therapies

Freitag

2007

Drug Development Research

View full text Add to dashboard Cite

Migraine preventive therapy includes treatment with pharmacological therapies that result in the reduction of the frequency, severity, or intensity of attacks. There are sufficient data to make recommendations for the following seven pharmacological agents for migraine prevention: topiramate, divalproex sodium, amitriptyline, metoprolol, propranolol, timolol, and Petasites. Additional evidence and treatment recommendations are reviewed on the specific efficacy and safety of several other therapies tested for migraine prevention. Drug Dev Res 68:315-320, 2007.

show abstract

“…Zolmitriptan, in doses of 1.25À5 mg, was investigated in a placebo-controlled study of a single menstrual migraine attack. 50 At a dose of 2.5 mg, oral naratriptan was evaluated in a randomized double-blind placebo-controlled study and it was found, in subjects receiving active drug, that a pain-free response was maintained from 4 to 24 hours. 51 Frovatriptan has been studied in several studies, and has demonstrated consistent results.…”

Section: Treatmentmentioning

confidence: 99%

Gender-Based Issues in Headache

Diamond

2015

Headache and Migraine Biology and Management

View full text Add to dashboard Cite

Efficacy and Tolerability of Oral Zolmitriptan in Menstrually Associated Migraine: A Randomized, Prospective, Parallel‐Group, Double‐blind, Placebo‐Controlled Study

Abstract: Oral zolmitriptan exhibits efficacy and good tolerability in the treatment of menstrually associated migraine. Improvement over placebo was observed as early as 30 minutes following treatment.

Cited by 76 publications

References 17 publications

A Review of the Pharmacokinetics, Pharmacodynamics and Efficacy of Zolmitriptan in the Acute Abortive Treatment of Migraine

A Review of the Pharmacokinetics, Pharmacodynamics and Efficacy of Zolmitriptan in the Acute Abortive Treatment of Migraine

Newer aspects of migraine preventive therapies

Gender-Based Issues in Headache

Contact Info

Product

Resources

About